The MitraClip is the first-in-class percutaneous therapy for mitral regurgitation. It is delivered from the femoral vein and can be used for degenerative or functional mitral regurgitation. In Singapore, the device was first approved for use in 2011. This review describes the device and discusses the data supporting its use and the regional experience to date. The MitraClip, given the early experience, should only be used after consideration by Heart Teams and only in appropriately selected patients.
INTRODUCTION
The MitraClip (Abbott Vascular, Abbott Park, IL, USA) is the first-in-class percutaneous therapy for mitral regurgitation. It is a transcatheter technology emulating the double-orifice surgical techniques to MR repair pioneered by Alfieri et al [1] [2] [3] . The device was CE-marked in Europe in March 2008 and approved for use in Australia in March 2011. The device has gained early clinical acceptance as a treatment option for high-surgical risk patients with severe mitral regurgitation (MR) in Europe [4] [5] [6] . It was recently approved for use in the USA for prohibitive-risk degenerative MR in March 2014. In Singapore, the device was first approved for use in 2011, with the first case in Asia performed successfully at the National Heart Centre Singapore in April 2011 7 . Since then, 46 cases have been performed at the centre.
DEVICE OVERVIEW
The MitraClip comprises of the clip itself, a clip delivery system, a guide, and a stabilizer (Fig.  1 ). The procedure is performed under general anaesthesia primarily with transoesophageal echocardiography (TEE) guidance although some fluoroscopy is used as well ( Fig. 2 ). General anaesthesia is required because of the continuous use of TEE guidance and the need for the patient to remain completely still for the procedure 6, 8 . The procedure may be performed in the cardiac catheterization laboratory or a hybrid operating theatre. The MitraClip is delivered via a 24F (~8mm diameter) guide in the femoral vein to the right atrium. A transseptal puncture is then performed and the MitraClip guide positioned in the left atrium. The MitraClip clip delivery system (CDS) is then advanced into the left atrium via the guide. Under TEE guidance, the MitraClip is then carefully positioned above the mitral valve leaflets, where the regurgitation is most severe. Transoesophageal echocardiography guidance is necessary to avoid cardiac structures such as at the aorta, the left atrial free wall etc. The MitraClip is then used to grasp the anterior and posterior mitral leaflets, creating a dual orifice mitral valve. More than one MitraClip may be used; not-infrequently, two clips are used. Transesophageal echocardiography interrogation for degree of residual mitral regurgitation and presence of any mitral stenosis is then performed. If MitraClip implantation is felt to be suboptimal, the device can be released, repositioned and the leaflets re-grasped. If the repair is felt to be adequate, the MitraClip is deployed and the delivery system removed. The ability to assess the Proceedings of Singapore Healthcare  Volume 24  Number 1  2015 patients require dual antiplatelet therapy (usually aspirin and clopidogrel) for a minimum of 1 month and single antiplatelet therapy for 6 months. This is to allow time for endothelialisation over the MitraClip and prevent thrombus formation over the MitraClip.
CLINICAL DATA
The EVEREST II randomised controlled trial valve characteristics before deployment of the MitraClip is an important advantage of the therapy as it allows the operator to make adjustments and improve the technical outcome. Similarly, the device may be withdrawn if the operator feels that an optimal result cannot be achieved.
The MitraClip itself is made of cobalt-chromium and is covered by Dacron fabric. After implantation, comparing conventional surgery to the MitraClip showed that the device was less efficacious compared to surgery but had superior safety 8 . This important randomised trial compared the use of the MitraClip against surgery in patients with either severe degenerative (e.g. mitral valve prolapse) or functional MR. Patients enrolled had to meet ACC/ AHA guidelines indications for surgical treatment. It should be noted that this trial included patients suitable for surgery or MitraClip, and therefore, were normal risk patients. The premise of the trial was that the MitraClip would be non-inferior and safer than surgery. The primary composite end point for efficacy was freedom from death, from surgery for mitral-valve dysfunction, and from grade 3+ or 4+ mitral regurgitation at 12 months. The primary safety end point was a composite of major adverse events within 30 days. The study found that although percutaneous repair was less effective at reducing mitral regurgitation than conventional surgery (55% vs. 73%, p=0.007), the procedure was associated with superior safety (15% vs. 48%, p<0.001) and similar improvements in clinical outcomes such as NYHA functional class and quality of life.
At the National Heart Centre Singapore, 46 cases were performed between April 2011 and June 2014, with 45 (97.8%) technical successes (defined as successful implantation of clip with MR ≤2+). Functional and degenerative MR were equally represented at 22 patients each while 2 patients had mixed pathology. The mean length of stay was 5 days, with the vast majority of patients staying 1 day in the coronary care unit.
Our experience was combined with the regional data and reported by the MitraClip Asia-Pacific Registry (MARS) registry. It includes data from eight different centres in five countries in the Asia-Pacific (Australia, China, Indonesia, Malaysia and Singapore) 9 . The primary efficacy outcome was reduction in MR to ≤2+ at 30 days. The safety outcome was 30-day freedom from major adverse events (MAE), defined as the composite of death, myocardial infarction, non-elective cardiac, renal failure, transfusion of ≥2 units of blood, ventilation for >48H, septicaemia, and new onset atrial fibrillation. A total of 142 patients underwent the MitraClip procedure from February 2011 to October 2013. Fifty-three point five per cent (76) patients had functional MR, 45.8% (65) had degenerative and 0.7% (1) had mixed MR. The acute procedural success rate was 93.7% (133). Seventy-six point eight per cent (109) of the patients had ≤2+ MR at 30 days compared to 0% (0) at baseline (p<0.001). Eighty-two point one per cent of the patients were in NYHA Class I-II at 30 days compared to 31.7% at baseline (p<0.001). These regional results show that the MitraClip procedure is effective in reducing mitral regurgitation and has favourable short-term safety outcomes when used appropriately.
CURRENT INDICATIONS
Although the MitraClip was designed for use in patients with degenerative MR, it has also been used in patients with functional MR. In fact, the worldwide use of the device has been more common in patients with functional MR [10] [11] [12] . The main reason for the greater use in functional MR patient is that these patients often have significant risk and open surgical repair/replacement has not been shown to improve mortality. Functional MR patients inevitably have depressed left ventricular function. Many have underlying ischaemic heart disease and may have undergone prior coronary artery bypass surgery or percutaneous coronary intervention. These patients tend to be older and have multiple comorbidities. All these contribute to the procedural risk of any surgery. In contrast, the MitraClip procedure is remarkably safe. In the EVEREST II trial, which included both degenerative and functional MR patients, the MitraClip was significantly safer than surgery 8 . However, this difference in composite major adverse outcome was driven largely by ventilation time and use of blood transfusions. Both are 'soft' adverse events. Rate of adverse events like mortality, stroke and myocardial infarction were similar between the two arms. For degenerative MR, there have been no trials directly comparing MitraClip against medical therapy, because the current standard of care is surgery (in patients who meet indications). On the other hand, for functional MR, there is no proven mortality benefit with conventional surgery, when compared to medical therapy; whilst for the MitraClip, these studies are being conducted.
Nonetheless, because the MitraClip is performed percutaneously via the venous system, bleeding risks are substantially lower. In addition, in these patients with significant surgical risk, the avoidance of sternotomy and cardiopulmonary bypass is a significant advantage. It should be noted that in patients with functional MR, surgery has never been conclusively shown to provide mortality benefit, when compared to medical therapy alone, although there appears to be functional and Proceedings of Singapore Healthcare  Volume 24  Number 1  2015 symptomatic improvement in some patients [13] [14] [15] [16] . For the MitraClip, there has been no randomised trial comparing it to medical therapy alone in functional MR patients. However, the MitraClip, similar to surgical therapy, has been shown to improve NHYA class status, quality-of-life, echocardiographic parameters (such as left ventricular chamber size) in patients with functional MR 8 . The ongoing COAPT and RESHAPE studies from the USA and Europe will hopefully provide data to better our understanding on the impact of the MitraClip in these patients.
CONTRAINDICATIONS
The MitraClip therapy has important contraindications. It should not be used if clinical indications for MR intervention are not met, or if meaningful clinical benefit to the patient is limited by severe comorbidities or if life expectancy is limited. Anatomic contraindications include the presence of excessively flail leaflets, mitral valve clefts, endocarditis, primarily commissural MR or pre-existing concomitant mitral stenosis. Some of these limitations are relative and have to be assessed on a case-by-case basis to weigh risks against potential benefits.
CONCLUSIONS
The MitraClip represents an exciting advancement in the arena of structural heart disease. It is the first percutaneous therapy available for severe MR and remains the most commonly used commercially available device in the Asia-Pacific region. In general, the MitraClip therapy should only be offered as a treatment option in the following considerations: 
5.
Patients should be on optimal medical therapy regardless of whether they receive the therapy.
6. Echocardiographic assessment demonstrates anatomic suitability.
